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Bioluminescence imaging is used for longitudinal evaluation of bacteria in live animals. Clear rela-
tions exist between bacterial numbers and their bioluminescence. However, bioluminescence images
of Staphylococcus aureus Xen29, S. aureus Xen36 and Escherichia coli Xen14 grown on tryptone soy agar
in Etests demonstrated increased bioluminescence at sub-MICs of different antibiotics. This study aimed
to further evaluate the inﬂuence of antibiotic pressure on bioluminescence in S. aureus Xen29. Biolumi-
nescence of S. aureus Xen29, grown planktonically in tryptone soy broth, was quantiﬁed in the absence
and presence of different concentrations of vancomycin, ciproﬂoxacin, erythromycin or chloramphenicol
and was related to expression of the luxA gene under antibiotic pressure measured using real-time PCR.
In the absence of antibiotics, staphylococcal bioluminescence increased over time until a maximum after
ca. 6h of growth, and subsequently decreased to the detection threshold after 24h of growth owing to
reduced bacterial metabolic activity. Up to MICs of the antibiotics, bioluminescence increased according
to a similar pattern up to 6h of growth, but after 24h bioluminescence was higher than in the absence of
antibiotics. Contrary to expectations, bioluminescence per organism (CFU) after different growth periods
in the absence and at MICs of different antibiotics decreased with increasing expression of luxA. Sum-
marising, antibiotic pressure impacts the relation between CFU and bioluminescence. Under antibiotic
pressure, bioluminescence is not controlled by luxA expression but by co-factors impacting the bacterial
metabolic activity. This conclusion is of utmost importance when evaluating antibiotic efﬁcacy in live
animals using bioluminescent bacterial strains.
© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.. Introduction
Over the past decades, increasing use of biomaterial implants
nd devices has been accompanied by a concurrent increase in
he incidence of biomaterial-associated infections (BAIs). BAIs have
ow become the main cause of prosthetic implant and device fail-
re [1], and patients with prosthetic joint infection, for instance,
nd themselves at a risk of mortality exceeding that of many can-
ers [2]. Along with the combined search and development of
ew antibiotic drugs to ﬁght bacterial resistance to antibiotics,
ew antimicrobial prophylactic and therapeutic measures have
een developed to treat bacterial bioﬁlms. Therewith, the need for
ppropriate methods to evaluate these measures in vitro and in
ivo has become of paramount importance, especially in case of
∗ Corresponding author. Tel.: +31 50 363 3124.
E-mail address: h.c.van.der.mei@umcg.nl (H.C. van der Mei).
ttp://dx.doi.org/10.1016/j.ijantimicag.2015.09.007
924-8579/© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rightsBAIswhere clinical trials aredifﬁcult, requiring largepatient groups
owing to the relatively low incidence of BAI. Recently, the combina-
tion of sensitive bio-optical imaging systems and the availability of
bioluminescent bacteria has enabled real-time non-invasive moni-
toring of the spatiotemporal persistence of bacteria in live animals,
and the number of in vitro- and in vivo-based papers relying
on bacterial bioluminescence as an indicator of bacterial persis-
tence is rapidly increasing [3–8]. Clear relations have been found
between bioluminescence arising from bacterially contaminated
biomaterials in animals and ex vivo bacterial counts after cultur-
ing organisms from explanted materials after sacriﬁce in multiple
papers [4,5,7–10].
Bioluminescent bacteria are genetically engineered by stably
integrating the lux operon into their genome or on a plasmid
and are equipped with a luciferase reporter system capable of
emitting visible light that can be detected by highly sensitive cam-
era systems [6]. The total bioluminescence observed depends on
the number of bacteria involved and the bioluminescence per
reserved.
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ndividual organism. Bioluminescence per organism is controlled
y ﬁve essential genes (luxABCDE) [11] as well as different co-
actors (Supplementary Fig. S1).
Although several studies have conﬁrmed that bioluminescence
elates well to bacterial numbers in a bioﬁlm [3,4], it has also been
eported that bioluminescence per individual organism changes
uring the different bacterial growth phases [7,12–14]. Further-
ore, discrepancies have been pointed out between the number
f viable bacteria in a bioﬁlm and their total bioluminescence
ollowing exposure to antibiotics [14]. For an illustration of this
henomenon, we present bioluminescence images overlaid on
lack & white photographs of the agar plates for Staphylococcus
ureus Xen29, S. aureus Xen36 and Escherichia coli Xen14 grown on
ryptone soy agar (TSA) in Etests against vancomycin, ciproﬂoxacin,
rythromycin and chloramphenicol pressures (Supplementary Fig.
2).
The aim of this study was to further evaluate the inﬂuence of
he presence of different antibiotics on staphylococcal biolumi-
escence and expression of luxA during growth in a commercially
vailable and often used [7,10,15] bioluminescent strain, namely S.
ureus Xen29.
. Materials and methods
.1. Bacterial strain
Staphylococcus aureus Xen29, originating from meticillin-
usceptible S. aureus ATCC 12600, was made bioluminescent by
nserting a modiﬁed Photorhabdus luminescens lux operon (lux-
BCDE) into the bacterial genome [9], situated within the open
eading frame of the hypothetical gene SA2154 [16]. The strain was
btained commercially from PerkinElmer (Waltham, MA).
.2. Total bioluminescence of S. aureus Xen29 in planktonic
ulture in the absence and presence of antibiotic pressure
Bacteria were cultured from cryopreservative beads onto
SA (Oxoid Ltd., Basingstoke, UK) in the presence of 200mg/L
anamycin and were incubated for 24h at 37 ◦C in ambient air.
rior to each experiment, one colony was used to inoculate 10mL
f tryptone soy broth (TSB) (Oxoid Ltd.) andwas planktonically cul-
ured at 37 ◦C for 24h in ambient air. Then, 500L of each culture
as used to inoculate 10mL of TSB growthmediumandwas plank-
onically grown at 37 ◦C with continuous shaking at 150 rpm for
6h. Staphylococci were suspended in TSB to a concentration of
×106 bacteria/mL as counted in a Bürker-Türk counting chamber.
Next, 200L aliquots of bacterial suspension in TSB with an
ntibiotic concentration of 0 (no antibiotic) up to its minimum
nhibitory concentration (MIC) were incubated at 37 ◦C in sterile
6-well plates (Falcon®; Corning Inc., Corning, NY). Total biolu-
inescence was measured over the area of each individual well
t 2, 3, 4, 5, 6 and 24h after inoculation using a highly sensitive,
ooled charge-coupled device camera (IVIS® Lumina Imaging Sys-
em; PerkinElmer) and was expressed as photons per second (p/s).
ote that the total bioluminescence observed is the product of bac-
erial bioluminescence per individual organism and the number of
FU in the well culture.
Four antibiotics were applied that differ in their mode of
ntibacterial action: vancomycin is an inhibitor of bacterial cell
all synthesis; ciproﬂoxacin is an inhibitor of bacterial nucleic acid
ynthesis; and erythromycin and chloramphenicol prevent bacte-
ial protein synthesis. MICs of S. aureus Xen29 against the different
ntibiotics were determined using Etest strips (AB BIODISK, Solna,
weden) on TSA and were read from the photographs presented
n Supplementary Fig. S2: 0.75mg/L for vancomycin; 0.31mg/L fortimicrobial Agents 46 (2015) 713–717
ciproﬂoxacin; 0.25mg/L for erythromycin; and 2.7mg/L for chlor-
amphenicol.
2.3. Number of viable bacteria
To determine the number of CFU responsible for the total
bioluminescence observed, staphylococci were grown for vari-
ous periods of time in the absence and presence of vancomycin,
ciproﬂoxacin, erythromycin or chloramphenicol at their MIC in
200mL of TSB. Aliquots of 1mL were taken from the bacterial sus-
pension at different time points and were serially diluted, after
which 100L of the diluted bacterial suspensions were plated on
TSA plates and were incubated at 37 ◦C. CFU were counted after
24h of incubation and were expressed as CFU/mL. From the same
200mL culture, 200L aliquots were taken and the total biolumi-
nescence (p/s)wasmeasured in a 96-well plate in order to calculate
the bioluminescence per CFU while accounting for the different
volumes (p/s/CFU).
2.4. RNA isolation and luxA expression
Expression of the luxA gene in S. aureus Xen29, harvested from
the same bacterial cultures as used for CFU determination, was
measured using real-time PCR as described previously [17] after
incubation for different times in the absence and presence of van-
comycin, ciproﬂoxacin, erythromycin or chloramphenicol at the
different MICs of the antibiotics.
The sequence of S. aureus NCTC 8325-4 was used to design
primer sets for gyrB and of P. luminescens for luxA (gyrB f3,
5′-ATATAGGATCGACTTCAGAG-3′; gyrB r4, 5′-TGAATATCAACTGG-
GATACC-3′; LuxA f1, 5′-GTATTTCTGAGGAGTGTGGT-3′; LuxA r2, 5′-
CTGTTATTCATATCCGTGCC-3′). Then, 100nM of each primer was
used under a two-step protocol with an annealing temperature of
60 ◦C.Under the selectedconditions, primerefﬁciencywasbetween
90% and 110% as determined using serial dilutions of chromosomal
DNA of S. aureus Xen29.
Total RNA was isolated from aliquots of the growing suspen-
sion after different time periods in the absence and presence of
the antibiotics up to 24h at their respective MICs. Bacteria were
harvested by centrifugation and were frozen at −80 ◦C. Samples
were thawed slowly on ice and RNA isolation was carried out
using a RiboPureTM-Bacteria Kit (Ambion, Foster City, CA). DNA
was removed using the Ambion® DNA-freeTM Kit (Applied Biosys-
tems, Foster City, CA) and the absence of genomic DNA was veriﬁed
by reverse transcription PCR (RT-PCR) prior to reverse transcrip-
tion. For all samples, 35 cycles of PCR using the gyrB primer set
did not result in any detectable signal, conﬁrming the absence of
genomic DNA in the RNA preparation. RNA concentrations were
determined using an ultraviolet spectrophotometer (NanoDrop,
Wilmington, DE), and 250ng of total RNA was used for cDNA
synthesis (iScriptTM; Bio-Rad, Veenendaal, The Netherlands). PCR
reactions were prepared in triplicate using a CAS-1200 pipetting
robot (Corbett Life Science, Sydney, Australia). Expression levels of
luxA in staphylococci were analysed using the 2−CT method [18]
with gyrB as reference and expressed per CFU.
3. Results
Total staphylococcal bioluminescence after 2, 3, 4, 5, 6 and 24h
of planktonic growthwas plotted as a function of antibiotic concen-
tration for each of the antibiotics involved (Fig. 1). In the absence
of antibiotics, staphylococcal bioluminescence increased over time
until amaximumoccurred after ca. 6h of growth, and subsequently
decreased to the detection threshold after 24h of growth owing to
reduced metabolic activity of the bacteria. Up to the MICs of the
S. Daghighi et al. / International Journal of Antimicrobial Agents 46 (2015) 713–717 715
Fig. 1. Total bioluminescence of Staphylococcus aureus Xen29 as a function of time measured in 200L of tryptone soy broth culture medium after planktonic growth
in the absence and presence of different antibiotic concentrations. Concentrations of antibiotics are expressed relative to the minimum inhibitory concentration (MIC) of
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tach antibiotic as determined by Etest (see also Supplementary Fig. S2). Data are
easurements with separate bacterial cultures.
ntibiotics, bioluminescence increased according to a similar pat-
ern up to 6h of growth, but after 24h bioluminescence was higher
han in the absence of antibiotic.
Fig. 2 shows the number of viable S. aureus Xen29 during plank-
onic growth as a function of time in the absence and presence of
ntibiotics at theirMIC, indicating that bacterial growth is inhibited
n presence of antibiotics, whereas after 24h of growth the num-
er of bacteria approached the number of bacteria grown in the
bsence of antibiotics.
To determine the bioluminescence per organismduring growth,
he total bioluminescence observed was divided by the number of
FUandwasplottedversusexpressionof the luxAgene (Fig. 3). Con-
rary to expectation, bioluminescence per organism after different
rowth times in the absence and at the MICs of the different antibi-
tics decreased signiﬁcantly with increasing expression of the luxA
ene.
. Discussion
Bacterial bioluminescence offers a valuable imaging modality
o monitor bacterial persistence in in vivo infection models based
n frequent observations that bioluminescence is proportional to
he number of viable bacteria in a bioﬁlm [4,5,7–10]. The current
tudy, however, shows that the presence of antibiotics not only
ffects the number of viable bacteria of S. aureus Xen29 but also
he bioluminescence per individual organism. Bioluminescenceted as the median with full ranges indicated by the bars over three independent
enhancements at sub-MIC antibiotic concentrations were also
observed for S. aureus Xen36 and Gram-negative E. coli Xen14
(Supplementary Fig. S2). This attests to the fact that various antibi-
otics with different modes of antibacterial action have a similar
effect on bacterial bioluminescence activity for Gram-positive S.
aureus and Gram-negative E. coli. Moreover, bioluminescence per
individual organism is not related to luxA gene expression (Fig. 3).
Although enhanced bioluminescence activities at sub-MICs
have been found before both for E. coli and S. aureus in the presence
of trimethoprim [12] and for S. aureusXen29 at sub-MIC concentra-
tions of vancomycin [10], the relationship with lux gene expression
has never been fully understood. In the literature, there is contro-
versy regarding the origin of variations in bioluminescence activity
during growth. Welham and Stekel found on the basis of enzymatic
model calculations that bioluminescence is hardly sensitive to co-
factors such as NADPH, ATP and oxygen concentration and that the
enzymatic luciferase system is mainly sensitive to the availabil-
ity of aldehydes, which are controlled by luxE and luxD expression
[19]. The results presented in Fig. 3, however, clearly indicate that
factors other than expression of lux genes inﬂuence the temporal
development of bioluminescence. luxA expression in the absence of
antibiotics was higher than under antibiotic pressure (see Fig. 3),
which resembles the known effect of repressed gene transcription
by sub-MICs of antibiotics, distinct from their growth inhibitory
effects [20]. Also, the negative correlation between biolumines-
cence and luxAgeneexpression in the absence andpresenceofMICs
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sig. 2. Number of CFU/mL of Staphylococcus aureus Xen29 as a function of time dur
heir minimum inhibitory concentration (MIC).
f different antibiotics indicate that factors other than expression
f lux genes control the temporal development of bioluminescence.
It has been suggested that the NADPH redox pool, necessary
or bacterial respiration to take place, reduces over time in the
tationary state in order to limit cell damage due to reactive oxy-
en products resulting from respiration. Therefore, NADPH, which
s crucial for bioluminescence to occur, has been identiﬁed [13]
s a good candidate to explain the low bioluminescence observed
ig. 3. Bioluminescence per organism as a function of luxA gene expression at various t
oy broth in the absence and presence of antibiotics at their minimum inhibitory conce
eparately grown cultures. The solid line represents linear ﬁt of the data points, whilst thnktonic growth in tryptone soy broth in the absence and presence of antibiotics at
24h after incubation (Fig. 1) in the absence of antibiotics. It is rea-
sonable to assume that antibiotics have a negative impact on the
respiratory processes in the cell, which may, as a defence strategy,
lead to an increase of the NADPH pool, therewith enhancing the
bioluminescence despite low luxA expression (see Fig. 3).
Enhanced bioluminescence under antibiotic pressure may not
always be noticed in in vivo experiments because antibiotics may
also inhibit bacterial growth, which will compensate and thereby
ime points during planktonic growth of Staphylococcus aureus Xen29 in tryptone
ntration (MIC). Data points represent the median over three measurements with
e dotted lines indicate the 95% conﬁdence intervals.
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in the terrestrial bacterium Photorhabdus luminescens. Mol Biosyst 2009;5:
68–76.S. Daghighi et al. / International Journa
bscure bioluminescence enhancement. In the current study, how-
ver, 24hafter inoculationan increasing total bioluminescencewas
bserved with increasing antibiotic concentrations despite the fact
hat the number of CFU was hardly affected by the presence of
ntibiotics (compare Figs. 1 and 2). Accordingly, the observation
hat different total bioluminescences emanate from equal num-
ers of bacteria yields the conclusion that total bioluminescence
oes not always correlate with CFU counts under antibiotic pres-
ure. This isprobablydue to thechangingconcentrationsof relevant
o-factors, such as NADPH, in a bacterium.
In conclusion, antibiotic pressure impacts the relation between
FU and bioluminescence. Under antibiotic pressure up to the MIC,
ioluminescence is not controlled by luxA gene expression and the
mpact of antibiotic pressure on bioluminescence in S. aureus is
anifested as a decrease in luxA expression and a likely enhanced
vailability of co-factors, such asNADPH.As a result, staphylococcal
ioluminescence per bacterium may increase under the inﬂuence
f antibiotics. This implies that the decrease of total biolumines-
ence frombacteria observed in vivounder antibiotic pressure does
ot necessarily correlate with eradication of viable bacteria. This
ffect is not always taken into account in the growing body of lit-
rature using bioluminescent bacteria, but must not be neglected
hen evaluating new antibiotic drugs in vitro or when interpre-
ing in vivo studies in animals using bioluminescence imaging of
acteria in the presence and absence of antibiotics.
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